HIV/AIDS shillfactor.net

Ho	Volberding	Hirsch	Mellors	Schooley
Why this matters	*	Procrit Pushers	*	Shillfactor blog

Martin S. Hirsch, MD

From the October 2006 revisions to the DHHS adult and adolescent HIV treatment guidelines (appendix A):

Dr. Hirsch reports serving on the Scientific Advisory Board of and receiving compensation from:
Cetek (a cancer biotech company with no HIV products)

and serves as an ad hoc consultant for:
Schering-Plough
(The company has an HIV drug in Phase II development and is also one of two companies that manufacture and sell pegylated interferon for the treatment of hepatitis C infection.)

2004 conflict of interest/competing interest disclosures for Martin Hirsch

From the DHHS treatment guidelines (10/29/2004)

Bristol-Myers Squibb: Ad hoc consultant, speaking honoraria
GlaxoSmithKline: Ad-hoc consultant
Schering: Ad-hoc consultant

Source: see new Appendix A, "DHHS Panel on Clinical Practices for Treatment of HIV Infection Conflict of Interest Disclosure – October 2004," of the DHHS "Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents" at http://www.aidsinfo.nih.gov/guidelines/adult/AA_102904.html#appendix (accessed March 26, 2005); †per 2000 disclosure

From the IAS treatment guidelines (07/14/2004)

Bristol-Myers Squibb: Ad hoc consultant
GlaxoSmithKline: Ad hoc consultant
Merck: Ad hoc consultant
Roche-Trimeris: Ad hoc consultant
Schering: Ad-hoc consultant
Takeda: Ad hoc consultant

Source: "Treatment for Adult HIV Infection: Recommendations of the International AIDS Society-USA Panel." JAMA 292(2): 251-265.

From a recent Continuing Medical Education (CME) module* at Medscape† (05/31/2005)

Acambis: Ad hoc consultant/advisor
Elixir: Grant support
GlaxoSmithKline: Ad hoc consultant/advisor
Merck: Ad hoc consultant/advisor
Takeda: Grant support

Source: "Highly Active Antiretroviral Therapy in 2005: Recent Data for Clinical Practice," released May 31, 2005 at http://hiv.medscape.com (accessed July 16, 2005)

*This CME clinical review update was supported by an independent educational grant from Bristol Myers-Squbb.

†Medscape is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

*********************************************************************************************************************************************
*****************************************************************************************************************************************

NOTE: While the concerns of commercial bias, corruption and kick-backs expressed here are serious and well-documented, they in no way endorse or support a thesis which denies any of the following:

(1) That HIV is necessary in the causation of the immune deficiency syndrome called AIDS;
(2) That HIV antibody tests accurately diagnose HIV in up to 98% of infected individuals after 4-12 weeks of infection;
(3) That antiretroviral medicines, while far from perfect, improve immune function and can extend life;
(4) That HIV is heterosexually as well as homosexually transmitted;
(5) That condoms, when used properly, can prevent HIV transmission;
(6) That HIV/AIDS is one of many serious public health challenges in many regions of Africa, Asia, and the Caribbean.

This site brought to you as an informational service and was definitively not made possible by a grant or gift--"educational," "unrestricted," or otherwise--by the likes of GlaxoSmithKline, Gilead, Bristol-Myers Squibb, Abbott, Tibotec-Virco, Pfizer, Merck, Monogram, Triangle, Trimeris, Boehringer Ingelheim, Roche, Schering, Panacos, Pharmasset, Shire, Ortho Biotech, (Orchestra Therapeutics), (Tanox), Genentech, Takeda, Vertex, (Bayer Diagnostics), Siemens, Acambis, Achillion, Adventrx, Anadys, (AnorMed), Genzyme, Avexa, Depomed, Idenix, Koronis, Millenium, Progenics, (Therapy Edge), Advanced Biological Concepts, VirXSys, Human Genome Sciences or any of the rest.